NasdaqGM - Nasdaq Real Time Price USD

Eliem Therapeutics, Inc. (ELYM)

Compare
6.99 -0.37 (-5.03%)
At close: August 30 at 4:00 PM EDT
6.60 -0.39 (-5.58%)
After hours: August 30 at 6:16 PM EDT
Loading Chart for ELYM
DELL
  • Previous Close 7.36
  • Open 7.37
  • Bid 6.76 x 100
  • Ask 7.28 x 100
  • Day's Range 6.80 - 7.51
  • 52 Week Range 2.35 - 11.55
  • Volume 1,109,041
  • Avg. Volume 222,103
  • Market Cap (intraday) 468.751M
  • Beta (5Y Monthly) -0.32
  • PE Ratio (TTM) --
  • EPS (TTM) -2.22
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

eliemtx.com

9

Full Time Employees

December 31

Fiscal Year Ends

Recent News: ELYM

View More

Performance Overview: ELYM

Trailing total returns as of 8/30/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

ELYM
158.89%
S&P 500
18.42%

1-Year Return

ELYM
158.89%
S&P 500
25.59%

3-Year Return

ELYM
73.91%
S&P 500
25.26%

5-Year Return

ELYM
56.98%
S&P 500
27.31%

Compare To: ELYM

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ELYM

View More

Valuation Measures

Annual
As of 8/30/2024
  • Market Cap

    467.41M

  • Enterprise Value

    244.37M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    2.10

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -24.54%

  • Return on Equity (ttm)

    -38.35%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -64.19M

  • Diluted EPS (ttm)

    -2.22

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    223.14M

  • Total Debt/Equity (mrq)

    0.05%

  • Levered Free Cash Flow (ttm)

    -29.91M

Research Analysis: ELYM

View More

Company Insights: ELYM

Research Reports: ELYM

View More

People Also Watch